CERTIFICA	ישיחי
OFFITTION	11:

STATE OF WISCONSIN)

CONTROLLED SUBSTANCES BOARD)



I, David P. Donarski, M.D., Chairperson of the controlled substances board and custodian of the official records of said board, do hereby certify that the annexed rules relating to the classification of specified substances in the uniform controlled substances act was duly approved and adopted by this board on April 15, 1993.

I further certify that this copy has been compared by me with the original on file with the Board and that this copy is a true copy of the original, and of the whole of the original.

IN TESTIMONY WHEREOF, I have hereunto set my hand at the State Capitol Building in the city of Madison, this 17th day of June, 1994.

David P. Donarski, M.D., Chairperson

ORDER OF THE CONTROLLED SUBSTANCES BOARD CREATING AND AMENDING RULES

NOTICE IS HEREBY GIVEN That pursuant to s. 161.24 Stats., and according to the procedure set forth in s. 227.16 (2)(e), Stats., the Controlled Substances Board will create CSB 2.22 amending s. 161.14 (2)(b), creating s. 161.16 (3)(gm), s. 161.14 (4)(bm), s. 161.14 (4)(cm), s. 161.14 (7)(am), and s. 161.14 (7)(ag) as herein proposed without public hearing, unless, within 30 days after publication of this notice it is petitioned for a public hearing by 25 persons who will be affected by the rule changes, a municipality which will be affected be the rule changes, or an association which is representative of a farm, labor, business or professional group which will be affected by the rule changes.

Analysis Prepared by the Controlled Substances Board

This order revises the controlled substances schedules of the Wisconsin Controlled Substances Act to bring them into conformity to the federal controlled substances act as required by s. 161.11 (4) Stats. The Drug Enforcement Administration, of the Department of Justice issued rules effective September 21, 1992 placing Aminorex in Schedule I; February 16, 1993 rules were issued placing cathinone and 2,5-dimethoxy-4-ethylamphetamine (DOET) into schedule I; March 12, 1993 rules were issued placing Alpha-ethyltryptamine into Schedule I and Levo-alphacetylmethadol was proposed to be move from Schedule I to Schedule II of the Controlled Substances Act. Under s.161.11 (4) Stats. the Wisconsin Uniform Controlled Substances Act the state is required to similarly control the substance.

Pursuant to authority vested in the Controlled Substances Board by ss. 161.11 (1), 161.11(4), and 161.24, the Controlled Substances Board proposes to adopt CSB 2.22 WI Administrative Code to revise various sections of ss. 161 as follows.

CSB 2.22 Additions to drug schedules.

- (1) Paragraph (b) of s. 161.14 (2) is amended to read:
- (b) Alphacetylmethadol (except Levo-alphacetylmethadol (LAAM))
- (2) Paragraph (cm) of s. 161.14 (4) is created to read:
- (cm) Alpha-ethyltryptamine, its optical isomers, salts and salts of isomers;
- (3) Paragraph (bm) of s. 161.14 (4) is created to read:
- (bm) 2,5-dimethoxy-4-ethylamphetamine, commonly as DOET;
- (4) Paragraph (am) of s. 161.14 (7) is created to read:
- (am) Aminorex, its salts, optical isomers, and salts of optical isomers;
- (5) Paragraph (ag) of s. 161.14 (7) is created to read:
- (ag) Cathinone;

(6) Paragraph (gm) of s. 161.16 (3) is created to read:

(gm) Levo-alphacetylmethadol (LAAM)

The rules contained in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register as provided in s. 227.22(2), Stats.

Wisconsin Controlled Substances Board

Date:

David Donarske, MD

Chair



State of Wisconsin \setminus controlled substances board

1 WEST WILSON STREET ROOM 418 P.O. BOX 7851 MADISON, WISCONSIN 53707-7851 (608) 266-7586 FAX (608) 266-1533

June 17, 1994

Mr. Bruce E. Munson Revisor of Statutes 131 W. Wilson St. Madison, WI 53703-3233



Dear Mr. Munson:

As provided in s. 227.20, State., there is hereby submitted a certified copy of CSB 2.22, administrative rules relating to additions, deletions, transfers, and amendments to the schedules of the controlled substances act, s. 161.

These rules are also being submitted to the Secretary of State as required by s. 227.20, Stats.

Market &.

These rules have minimal effect on small businesses as defined in s. 227.114(1)(a), Stats. Pharmacies are required to report the sale of these drugs because of Federal and other state regulations and this does not increase the burden. The reduction of scheduling in the instance of pentazocine will decrease the reporting burden on physicians and pharmacies.

Sincerely,

David P. Donarski, M.D.

Chairperson

Enclosure